Media Details

  • Home
  • Media
  • Details
  2020-09-21 19:40:26

Ho Wah Genting Berhad’s JV appoints Dr. John Andrews to support FDA appplication for COVID-19 vaccine clinical trials

KUALA LUMPUR, 21 SEPTEMBER 2020Ho Wah Genting Berhad (“HWGB” or the “Company”) (Bursa Stock Code:9601) through its wholly owned subsidiary HWGB Biotech Sdn Bhd’s (“HWGB Biotech”) [formerly known as HWG Consortium Sdn Bhd] together with its joint venture partner US based E-MO Biology Inc (“EBI”) (“JV”) contracted Dr. John Andrews through Black Diamond Networks (Professional service agreement) to support its JV’s US FDA IND application project in view of/advancing on his 25 years direct experiences in vaccine development & clinical phase IV study.
Dr. Andrews has spent the majority of his in career developing antivirals and other drugs of importance such as infectious diseases, autism, oncology, CV, pulmonary and has extensive experience with presentation to both the Center for Drug Evaluation and Research (CDER) and  Center for Biologics Evaluation and Research (CBER). 
Dr. Andrews has also served  in the Data and Safety Monitoring Board (DSMB) as a Safety Review Officer for several vaccine development programs both in the private sector and with governments agencies.
HWGB chief executive officer Dato’ Aaron Lim expressed: “"I'm delighted to welcome Dr. Andrews to the team. He is a seasoned expert in vaccine development programs both in the private sector and with governments agencies. The appointment of Dr Andrews is timely and his experience and expertise will propel the efforts for the company to gain traction in developing a vaccine for COVID-19.”
"Dr. Andrews will help us pursue the strategic vision in the development of poliomyelitis virus vaccine (PVV) for the treatment of COVID-19," he said.
EBI will undertake Phase IV clinical trials for a new indication which proposes the use of existing poliomyelitis virus vaccines for prevention of COVID-19 (“Project”) and the research and development, testing, registration, commercialization and other activities relating to the 5 provisional patent applications (“Patents”), subject to the approval from the Food and Drug Administration (FDA)  on the Investigational New Drug (IND) application.
EBI had on 15 June 2020 submitted the IND application to the FDA to conduct phase IV clinical trials for a new indication using existing PVV for prevention of COVID-19. Furthermore, on 28 August 2020, the FDA has responded to the second communication EBI with FDA by requesting EBI to provide further information on the IND application too.
HWGB Biotech will invest US$1 million and be entitled to 40% of the total net profit as a sponsor of EBI. Furthermore, HWGB Biotech will enjoy exclusive licence and rights for the production, distribution, marketing, commercialization and the sale of the repurposed vaccine based on the polio vaccine for use in preventing COVID-19 infections in Southeast Asia countries.
Early this month, HWGB Biotech had also submitted the necessary documents to the National Medical Research Register (NMRR) in Malaysia to evaluate oral polio vaccine's (OPV) effectiveness and as a preventive protection against the COVID-19.
Ho Wah Genting Berhad (“HWGB” or the “Company”) is principally engaged in investment holdings and the provision of management services to its subsidiaries. The Company had on 30 June 2020 diversified its existing businesses to include healthcare related industry which mainly involved in Health Supplement, Biotechnology and Health Technology. In addition, the Company and its subsidiaries (“HWGB Group” or the “Group”) are also engaging in the businesses of Investment holdings; manufacturing of wire and cable and moulded power supply cord sets and cable assemblies for electrical and electronic devices and equipment; trading of wire and cable; and travel agent and tour related services.
For more information about HWGB Biotech, please visit and/or 
Please also feel free to subscribe to our newsletter online to get latest exciting developments of our new ventures. Click on

E-Mo Biology Inc (“EBI”) was incorporated in the state of California in the United States of America on 24 May 2020. It is principally involved in conducting biology research and development activities and is the sponsor of a study which indicates booster polio vaccine to reduce COVID-19 SARS-COV-2 infection and severity.
EBI is founded by Xie QiYi, who serves as Managing Director of EBI. He has over 30 years of experiences in areas of public health and infection disease control. He was also involved in the development of medical and diagnostic devices, with focus on Quality, Regulatory and Clinical Affairs for quality systems.
Black Diamond Networks is a professional staffing agency filling roles in the life science, engineering, and information technology sectors. Through the rapid deployment of experienced, pre-screened personnel, the Company enable customers to meet projects goals and deadlines and address critical staffing needs while maintaining headcount, payroll and administrative flexibility.
The Company network of contract professionals has been directly sourced through active recruiting methods and referrals from other trusted contractors and customers. Their vetting includes seeking additional endorsements, as well as thorough interviews to determine experience, skill level, assignment preferences and compatibility, and logistical requirements. Through the diligence they assembled a national network of on-demand contractors with specific talent for hard-to-fill positions.
Black Diamond Networks maintain regular contact with their contractors throughout the contractor’s assignment through their Contractor Care program, in which a dedicated in-house manager addresses contractor concerns before they become problems. That attention allows the contractor to stay satisfied at his job and productive for their client.